Sign In
Buy VRNA
$106.91
+0 (+0%)
At Close: Jan 06, 2026
Verona Pharma Is Launching Ohtuvayre, Although There Will Be Competition
09:00am, Sunday, 30'th Jun 2024
VRNA received FDA approval for ensifentrine (Ohtuvayre) for the maintenance treatment of COPD on June 26. SNY/REGN's Dupixent represents a potential competitor. As do other drugs in development from S
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
09:49am, Thursday, 27'th Jun 2024
On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.
Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month
09:03am, Thursday, 27'th Jun 2024
Verona Pharma's therapy for treating a chronic lung disease will be sold in the U.S. at a wholesale price of $2,950 per month, the U.K.-based company said on a conference call on Thursday.
US FDA approves Verona Pharma's therapy for 'smoker's lungs'
05:13pm, Wednesday, 26'th Jun 2024
The U.S. Food and Drug Administration has granted approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)
04:57pm, Wednesday, 26'th Jun 2024
Ohtuvayre is indicated for the maintenance treatment of COPD allowing for broad use in COPD patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects
Verona Pharma plc (VRNA) Q1 2024 Earnings Call Transcript
12:31pm, Thursday, 09'th May 2024
Verona Pharma plc (NASDAQ:VRNA ) Q1 2024 Results Conference Call May 9, 2024 9:00 AM ET Company Participants David Zaccardelli - President, CEO & Executive Director Mark Hahn - Chief Financial Officer
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:15am, Thursday, 09'th May 2024
PDUFA Target Action Date for Ensifentrine of June 26, 2024 Finalizing commercial launch preparations Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
07:00am, Thursday, 09'th May 2024
Non-dilutive funding will support planned US commercial launch and expansion of ensifentrine's clinical activities
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
02:00am, Thursday, 02'nd May 2024
PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine, an investigational, first-in-class, selective, dual inhibitor of PDE3 and PD
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
02:00am, Thursday, 25'th Apr 2024
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fir
Andrew Fisher Joins Verona Pharma as General Counsel
02:00am, Monday, 04'th Mar 2024
LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces Mr.
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
08:45am, Friday, 01'st Mar 2024
Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this y
Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
02:00am, Thursday, 29'th Feb 2024
PDUFA Target Action Date for ensifentrine of June 26, 2024 Commercialization preparations advance Strong balance sheet supports commercialization and Company's growth Conference call today at 9:00 a.m
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
02:00am, Thursday, 15'th Feb 2024
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the four
Michael Austwick Joins Verona Pharma as Non-Executive Director
02:00am, Thursday, 01'st Feb 2024
LONDON and RALEIGH, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) announces Mr. Michael Austwick has today joined the board as a Non-Executive Director
